Ottobock


Ottobock 3Q26: Solid quarter despite B2C headwinds

12/11/26 -"Ottobock delivered a solid 3Q26, in line on sales and slightly ahead on profitability. Core revenues grew by +9.0% to €433.4m (organic +6.4%). B2B (+9.9% organic) and an APAC rebound (+17.9%) offset ..."

Pages
78
Language
English
Published on
12/11/26
You may also be interested by these reports :
12/11/26
Ottobock delivered a solid 3Q26, in line on sales and slightly ahead on profitability. Core revenues grew by +9.0% to €433.4m (organic +6.4%). B2B ...

11/11/26
The Q3 sales and profitability met expectations; however, a slight guidance downgrade disappointed investors. Healthy growth in all sub-segments was ...

09/11/26
Qiagen’s Q3 results exceeded management’s guidance, with sales primarily driven by Sample Technologies and Genomics/NGS. However, challenges in US ...

06/11/26
In early September 2026, we suggested that the 5 lean years for MedTechs performance had maybe reached an end. Bingo. The following chart confirms ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO